Activated Factor X Delivered by Adeno-associated Virus Significantly Inhibited Bleeding and Alleviated Hemophilic Synovitis in Hemophilic Mice

Overview

Journal Gene Ther

Date 2024 Sep 10

PMID 39256611

Authors

Feixu Zhang

Xinyue Zhou

Baolai Hua

Xinyi He

Zhanao Li

Xiao Xiao

Xia Wu

Affiliations

Soon will be listed here.

Abstract

In hemophilia, deficiency of factor VIII or IX prevents the activation of the common coagulation pathway, and inhibits the conversion of FX to activated FXa, which is required for thrombin generation. We hypothesized that the direct expressed FXa has the potential to activate the common pathway and restore coagulation in hemophilia patients. In this study, the cassettes that expressed FXa, FXaop and FXa-FVII were packaged into an engineered AAV capsid, AAV843, and were delivered into hemophilia A and B mice by intravenous injection. AAV-FXaop could be stably expressed in vivo and showed the best immediate and prolonged hemostatic effects, similar to those of commercial drugs (Xyntha and Benefix). AAV-FXaop also significantly inhibited bleeding in hemophilia A mice with inhibitors. In addition, FXa expression in joints significantly alleviated the occurrence of hemophilic synovitis. AAV-delivered FXa may be a novel target for treating hemophilic and hemophilic synovitis.

References

Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe S . WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26 Suppl 6:1-158. DOI: 10.1111/hae.14046. View

Kenet G, Chen Y, Lowe G, Percy C, Tran H, von Drygalski A . Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study. J Clin Med. 2021; 10(24). PMC: 8705574. DOI: 10.3390/jcm10245959. View

Callaghan M, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M . Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021; 137(16):2231-2242. PMC: 8065240. DOI: 10.1182/blood.2020009217. View

Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso M . Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018; 379(9):811-822. DOI: 10.1056/NEJMoa1803550. View

Wight J, Paisley S . The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003; 9(4):418-35. DOI: 10.1046/j.1365-2516.2003.00780.x. View

Martensson A, Letelier A, Hallden C, Ljung R . Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations. Haemophilia. 2015; 22(3):440-5. DOI: 10.1111/hae.12854. View

Guh S, Grosse S, McAlister S, Kessler C, Soucie J . Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia. 2011; 18(2):276-83. PMC: 4684173. DOI: 10.1111/j.1365-2516.2011.02713.x. View

Brown K, Green G . The haemophilia drug market. Nat Rev Drug Discov. 2018; 17(8):541-542. DOI: 10.1038/nrd.2018.54. View

Camire R . Bioengineering factor Xa to treat bleeding. Thromb Res. 2016; 141 Suppl 2:S31-3. DOI: 10.1016/S0049-3848(16)30360-7. View

10.

George L, Thalji N, Raffini L, Gimotty P, Camire R . Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L). J Thromb Haemost. 2015; 13(9):1694-8. DOI: 10.1111/jth.13059. View

11.

Ivanciu L, Camire R . Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity. Blood. 2015; 126(1):94-102. PMC: 4492200. DOI: 10.1182/blood-2015-03-634329. View

12.

Thalji N, Camire R . Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol. 2017; 24(5):453-459. PMC: 5629015. DOI: 10.1097/MOH.0000000000000369. View

13.

Parsons-Rich D, Hua F, Li G, Kantaridis C, Pittman D, Arkin S . Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa ). J Thromb Haemost. 2017; 15(5):931-937. DOI: 10.1111/jth.13673. View

14.

Sun J, Hakobyan N, Valentino L, Feldman B, Samulski R, Monahan P . Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood. 2008; 112(12):4532-41. PMC: 2954682. DOI: 10.1182/blood-2008-01-131417. View

15.

Sun J, Hua B, Livingston E, Taves S, Johansen P, Hoffman M . Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis. Blood. 2017; 129(15):2161-2171. PMC: 5391623. DOI: 10.1182/blood-2016-08-734053. View

16.

Hakobyan N, Enockson C, Cole A, Sumner D, Valentino L . Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia. 2008; 14(4):804-9. DOI: 10.1111/j.1365-2516.2008.01689.x. View

17.

Sang Y, Roest M, de Laat B, de Groot P, Huskens D . Interplay between platelets and coagulation. Blood Rev. 2020; 46:100733. PMC: 7354275. DOI: 10.1016/j.blre.2020.100733. View

18.

Yang L, Jiang J, Drouin L, Agbandje-Mckenna M, Chen C, Qiao C . A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A. 2009; 106(10):3946-51. PMC: 2656185. DOI: 10.1073/pnas.0813207106. View

19.

Yang L, Li J, Xiao X . Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol. 2011; 709:127-39. DOI: 10.1007/978-1-61737-982-6_8. View

20.

Xue F, Li H, Wu X, Liu W, Zhang F, Tang D . Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. Lancet Haematol. 2022; 9(7):e504-e513. DOI: 10.1016/S2352-3026(22)00113-2. View